NEW YORK, Oct 18 (Reuters) - Schering-Plough Corp. SGP.N said an
advisory panel to Europe's drug regulators recommended approving the
company's Caelyx drug as a stand-alone therapy for breast cancer
patients who have an increased risk of heart attacks.
The Committee for Proprietary Medicinal Products, the main advisory
body to the European Commission, which is charged with approving or
rejecting the drug, issued a "positive opinion" recommending
approval of Caelyx, Schering-Plough said.
Caelyx is already marketed in the 15-nation European Union for the
treatment of advanced ovarian cancer in women who have failed the
standard platinum-based therapy. The drug is also sold as a
treatment for an AIDS-related skin disorder known as Kaposi's
Schering-Plough, which is based in Kenilworth, New Jersey, has
exclusive non-U.S. licensing rights to the drug, except in Japan and
Israel, through a distribution agreement with a subsidiary of
Johnson & Johnson JNJ.N .
The drug is marketed in the United States under the brand name Doxil
by Johnson & Johnson.